Michael Wohlfeiler

1.4k total citations · 1 hit paper
31 papers, 1.1k citations indexed

About

Michael Wohlfeiler is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Michael Wohlfeiler has authored 31 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Infectious Diseases, 15 papers in Virology and 9 papers in Epidemiology. Recurrent topics in Michael Wohlfeiler's work include HIV/AIDS drug development and treatment (22 papers), HIV/AIDS Research and Interventions (19 papers) and HIV Research and Treatment (15 papers). Michael Wohlfeiler is often cited by papers focused on HIV/AIDS drug development and treatment (22 papers), HIV/AIDS Research and Interventions (19 papers) and HIV Research and Treatment (15 papers). Michael Wohlfeiler collaborates with scholars based in United States, United Kingdom and Ireland. Michael Wohlfeiler's co-authors include Jacob Lalezari, Michael W. Dunne, Nathan Clumeck, Anders Karlsson, Howard Mayer, John F. Sullivan, Andrzej Horban, Bonaventura Clotet, Caroline E. Ridgway and James Goodrich and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Michael Wohlfeiler

28 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

2008 570 citations Roy M. Gulick, Jacob Lalezari et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Wohlfeiler United States	14	758	637	280	209	107	31	1.1k
Nicola Gianotti Italy	21	1.2k 1.6×	1.1k 1.7×	306 1.1×	305 1.5×	58 0.5×	153	1.5k
Jean-Louis Sankalé United States	20	752 1.0×	802 1.3×	297 1.1×	114 0.5×	122 1.1×	29	1.1k
Eugène Kroon Thailand	20	874 1.2×	838 1.3×	310 1.1×	197 0.9×	147 1.4×	68	1.1k
Maria Franca Pirillo Italy	19	933 1.2×	539 0.8×	378 1.4×	179 0.9×	127 1.2×	58	1.3k
Grace Peng United States	18	1.1k 1.5×	790 1.2×	430 1.5×	578 2.8×	84 0.8×	25	1.5k
Charles Craig United States	17	851 1.1×	747 1.2×	240 0.9×	65 0.3×	73 0.7×	38	1.1k
Stephen Becker United States	18	654 0.9×	440 0.7×	199 0.7×	164 0.8×	169 1.6×	33	974
Anne Willoughby United States	14	667 0.9×	527 0.8×	368 1.3×	157 0.8×	210 2.0×	20	1.1k
Susan L. Ford United States	22	1.5k 2.0×	1.1k 1.7×	391 1.4×	215 1.0×	35 0.3×	56	1.8k
Maria Cecília Araripe Sucupira Brazil	18	654 0.9×	646 1.0×	252 0.9×	45 0.2×	102 1.0×	59	966

Countries citing papers authored by Michael Wohlfeiler

Since Specialization

Citations

This map shows the geographic impact of Michael Wohlfeiler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Wohlfeiler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Wohlfeiler more than expected).

Fields of papers citing papers by Michael Wohlfeiler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Wohlfeiler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Wohlfeiler. The network helps show where Michael Wohlfeiler may publish in the future.

Co-authorship network of co-authors of Michael Wohlfeiler

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Wohlfeiler. A scholar is included among the top collaborators of Michael Wohlfeiler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Wohlfeiler. Michael Wohlfeiler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dieterich, Douglas T., Laurence Brunet, Karam Mounzer, et al.. (2025). Monitoring and risk of hepatitis B reactivation and hepatitis flare during tenofovir interruption among people with HIV and hepatitis B. AIDS. 40(1). 43–51.

Pierone, Gerald, Jennifer S Fusco, Laurence Brunet, et al.. (2024). Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States. AIDS Research and Therapy. 21(1). 76–76. 1 indexed citations

Pierone, Gerald, Laurence Brunet, Jennifer S Fusco, et al.. (2024). Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care. HIV/AIDS - Research and Palliative Care. Volume 16. 133–140.

Dieterich, Douglas T., Laurence Brunet, Ricky Hsu, et al.. (2024). WED-405 Tenofovir disoproxil fumarate and tenofovir alafenamide interruption in hepatitis B and human immunodeficiency virus co-infected individuals in the United States: monitoring practices and incidence of hepatitis B reactivation or hepatitis flare. Journal of Hepatology. 80. S799–S800. 1 indexed citations

Wohlfeiler, Michael, Rachel Palmieri Weber, Laurence Brunet, et al.. (2023). Definition, Burden, and Predictors of HIV-Associated Wasting and Low Weight in the OPERA Cohort. AIDS Research and Human Retroviruses. 39(12). 636–643.

Sension, Michael, Laurence Brunet, Jennifer S Fusco, et al.. (2023). Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort. Infectious Diseases and Therapy. 12(12). 2807–2817. 30 indexed citations

Sension, Michael, Jennifer S Fusco, Laurence Brunet, et al.. (2023). 1608. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA® Cohort. Open Forum Infectious Diseases. 10(Supplement_2). 7 indexed citations

Sension, Michael, Jennifer S Fusco, Laurence Brunet, et al.. (2023). 1028. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA® Cohort. Open Forum Infectious Diseases. 10(Supplement_2). 17 indexed citations

Mallon, Patrick, Laurence Brunet, Jennifer S Fusco, et al.. (2021). Weight gain before and after switch from TDF to TAF in a U.S. cohort study. Journal of the International AIDS Society. 24(4). e25702–e25702. 95 indexed citations

10.

Brunet, Laurence, Patrick Mallon, Jennifer S Fusco, et al.. (2021). Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization. Clinical Drug Investigation. 41(11). 955–965. 13 indexed citations

11.

Mills, Anthony, Kathy L. Schulman, Jennifer S Fusco, et al.. (2021). Virologic Outcomes Among People Living With Human Immunodeficiency Virus With High Pretherapy Viral Load Burden Initiating on Common Core Agents. Open Forum Infectious Diseases. 8(8). ofab363–ofab363. 3 indexed citations

12.

Mallon, Patrick, Laurence Brunet, Jennifer S Fusco, et al.. (2021). Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides. Open Forum Infectious Diseases. 9(1). ofab621–ofab621. 31 indexed citations

13.

Hsu, Ricky, Laurence Brunet, Jennifer S Fusco, et al.. (2020). Risk of chronic kidney disease in people living with HIV by tenofovir disoproxil fumarate (TDF) use and baseline D:A:D chronic kidney disease risk score. HIV Medicine. 22(5). 325–333. 11 indexed citations

14.

Wohlfeiler, Michael, Karam Mounzer, Laurence Brunet, et al.. (2020). Antiretroviral therapy and liver disorders in the OPERA^® cohort. Therapeutic Advances in Drug Safety. 11. 585518905–585518905. 1 indexed citations

15.

Czarnogorski, Maggie, Cindy Garris, Paul Wannamaker, et al.. (2020). 1037. Qualitative Findings from a Hybrid III Implementation-Effectiveness Study to Explore Perspectives of Health-care Staff on Early Implementation of Cabotegravir and Rilpivirine Long Acting (CAB+RPV LA) Injectable HIV treatment in the US (CUSTOMIZE). Open Forum Infectious Diseases. 7(Supplement_1). S549–S549. 1 indexed citations

16.

Cox, Joseph, Cassidy A. Gutner, Nadine Kronfli, et al.. (2019). A need for implementation science to optimise the use of evidence-based interventions in HIV care: A systematic literature review. PLoS ONE. 14(8). e0220060–e0220060. 17 indexed citations

17.

Hsu, Ricky, Jennifer S Fusco, Cassidy Henegar, et al.. (2018). Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database. Therapeutic Advances in Drug Safety. 9(12). 675–686. 7 indexed citations

18.

Hoover, Karen W., Kimberly Workowski, Félix Carpio, et al.. (2010). STD Screening of HIV-Infected MSM in HIV Clinics. Sexually Transmitted Diseases. 37(12). 771–776. 82 indexed citations

19.

Gulick, Roy M., Jacob Lalezari, James Goodrich, et al.. (2008). Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. New England Journal of Medicine. 359(14). 1429–1441. 570 indexed citations breakdown →

20.

Wohlfeiler, Michael, et al.. (2003). Pancreatitis Treated with Didanosine and Tenofovir Disoproxil Fumarate. Clinical Infectious Diseases. 37(5). e57–e62. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact